At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR Outcomes trial. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...
Zeist, Netherlands, April 22, 2024 — We proudly welcome Stefan Timmerman as our new Chief Financial Officer (CFO), effective April 1st, following up Eelco Brouwer, who played a crucial role in the completion of the Ampersand transaction last yea...
Zeist, Netherlands, April 5, 2024 — We’re proud to announce the appointment of Ricard Quingles Blasi as our new Chief Business Officer (CBO). With over 25 years of dynamic leadership experience, Ricard Quingles Blasi brings a wealth of strate...
LIVE WEBINAR | NOVEMBER 26 - 2024 | 17.00 CET Time to event trial designs in ALS: How useful are they? During the webinar hosted by Lieza Exalto, Ruben van Eijk, Lotte Smets and Jordi van Unnik will touch upon:An introduction to event-driv...
On the 27th of June, we organized the webinar: 'Clinical Consequences of the New MASLD Nomenclature' with guest speaker Prof. Maja Thiele.During this webinar, our speaker and hosts dived into the following topics:Is the MASLD nomeclature...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...
Utrecht, The Netherlands, 05-02-2024GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunc...
On March 12th, we organised the webinar: Getting GRIP on MASH after LITMUSDuring this webinar, our speaker and hosts explored the following topics:The usefulness of noninvasive diagnostic methods depends on the prevalence of the disease ...
Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners Partnership will further expand Julius’ clinical trial services capabilities to advance new therapeutics.Zeist, Netherlands, November 28, 2023 -- Julius Cli...
We are excited to announce that Julius Clinical has a brand-new look and website as part of the ongoing evolution of our company’s brand.Why? Ever since its foundation in 2008, Julius Clinical has been based on a unique triangle of scientif...
"*" indicates required fields
"*" indicates required fields
